etidronic acid Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
calcium metabolism regulator, pharmaceutical aid 1098 2809-21-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • etidronic acid
  • ethidronate
  • ethydronate
  • etidronate
  • hydroxyethanediphosphonic acid
  • oxyethylidenediphosphonic acid
  • etidronate disodium
A diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover.
  • Molecular weight: 206.03
  • Formula: C2H8O7P2
  • CLOGP: -2.54
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 5
  • TPSA: 135.29
  • ALOGS: -1.25
  • ROTB: 2

  • Status: OFM

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.40 g O
1.50 g P
0.40 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 97.07 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 5 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
Sept. 1, 1977 FDA PROCTER AND GAMBLE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Atypical femur fracture 58.14 31.42 15 1070 4982 46679995
Lip blister 38.15 31.42 9 1076 2066 46682911
Femur fracture 31.74 31.42 16 1069 36981 46647996

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event

Pharmacologic Action:

SourceCodeDescription
ATC M05BA01 MUSCULO-SKELETAL SYSTEM
DRUGS FOR TREATMENT OF BONE DISEASES
DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION
Bisphosphonates
ATC M05BB01 MUSCULO-SKELETAL SYSTEM
DRUGS FOR TREATMENT OF BONE DISEASES
DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION
Bisphosphonates, combinations
FDA CS M0006519 Diphosphonates
FDA EPC N0000175579 Bisphosphonate
CHEBI has role CHEBI:35610 cytostatic
CHEBI has role CHEBI:38161 chelating agent
CHEBI has role CHEBI:50646 anti-osteoporotics
MeSH PA D050071 Bone Density Conservation Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Osteitis deformans indication 2089002 DOID:5408
Humoral hypercalcemia of malignancy indication 47709007
Heterotopic ossification indication 128491006
Prevention of Glucocorticoid-Induced Osteoporosis off-label use
Gastritis contraindication 4556007 DOID:4029
Hypocalcemia contraindication 5291005
Peptic ulcer contraindication 13200003 DOID:750
Esophagitis contraindication 16761005 DOID:11963
Hyperphosphatemia contraindication 20165001 DOID:0050459
Swallowing painful contraindication 30233002
Ulcer of esophagus contraindication 30811009
Vitamin D deficiency contraindication 34713006
Infectious disease contraindication 40733004
Dysphagia contraindication 40739000
Periodontitis contraindication 41565005 DOID:824
Enterocolitis contraindication 43752006
Achalasia of esophagus contraindication 45564002 DOID:9164
Stricture of esophagus contraindication 63305008
Blood coagulation disorder contraindication 64779008 DOID:1247
Duodenitis contraindication 72007001 DOID:8643
Heart failure contraindication 84114007 DOID:6000
Kidney disease contraindication 90708001 DOID:557
Fracture of bone contraindication 125605004
Asthma contraindication 195967001 DOID:2841
Esophageal dysmotility contraindication 266434009 DOID:9192
Anemia contraindication 271737000 DOID:2355
Primary malignant neoplasm contraindication 372087000
Aseptic necrosis of bone of jaw contraindication 441809006
Invasive Dental Procedure contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 1.29 acidic
pKa2 5.36 acidic
pKa3 6.35 acidic
pKa4 10.42 acidic
pKa5 12.86 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
N0000007216 NUI
D00314 KEGG_DRUG
7414-83-7 SECONDARY_CAS_RN
4018878 VANDF
4019753 VANDF
C0086268 UMLSCUI
CHEBI:4907 CHEBI
911 PDB_CHEM_ID
CHEMBL871 ChEMBL_ID
CHEMBL1201042 ChEMBL_ID
DB01077 DRUGBANK_ID
D012968 MESH_DESCRIPTOR_UI
3305 PUBCHEM_CID
7184 IUPHAR_LIGAND_ID
2758 INN_ID
M16PXG993G UNII
1356715 RXNORM
4706 MMSL
81273 MMSL
d00599 MMSL
002143 NDDF
004883 NDDF
372908005 SNOMEDCT_US
387581008 SNOMEDCT_US
420702005 SNOMEDCT_US
96284009 SNOMEDCT_US

Pharmaceutical products:

None